SCHEDULE 13D/A 0001104659-21-112194 0000042872 XXXXXXXX LIVE 4 Common Stock, par value $0.0001 per share 05/13/2025 false 0001818382 020751103 HUMACYTE, INC.

2525 East North Carolina Highway 54 Durham NC 27713

Robert A. Grauman 646 202-2932 145 West 86 Street New York NY 10024 Thomas D. Brouillard 781 699 9000 Fresenius Medical Care Holdings, Inc. 920 Winter Street Waltham MA 02451-1547 Christof Koester 011 49 6172 609 0 Fresenius Medical Care AG Else-Kroener Strasse 1 Bad Homburg 2M 61352 0000042872 N Fresenius Medical Care Holdings, Inc. WC N NY 0.00 18312735.00 0.00 18312735.00 18312735.00 N 11.8 CO 0001333141 N Fresenius Medical Care AG AF N 2M 0.00 18312735.00 0.00 18312735.00 18312735.00 N 11.8 CO Common Stock, par value $0.0001 per share HUMACYTE, INC. 2525 East North Carolina Highway 54 Durham NC 27713 This Amendment No. 4 amends certain items of the Schedule 13D originally filed on September 2, 2021, as previously amended by Amendment No. 1 filed on December 1, 2023, by Amendment No. 2 filed March 7, 2024, and by Amendment No 3 filed on November 18, 2024 (as so amended, the "Schedule 13D") by Fresenius Medical Care Holdings, Inc., a New York Corporation ("FMCH") and Fresenius Medical Care AG a German stock corporation ("FME AG") with respect to the common stock, par value $0.0001 per share (the "Common Stock") of Humacyte, Inc., a Delaware corporation, formerly known as Alpha Healthcare Acquisition Corp. (the "Issuer" or "Humacyte"). Capitalized terms not otherwise defined herein have the meanings set forth in the Schedule 13D. Except as provided herein, this Amendment No. 4 does not modify any of the information previously reported on the Schedule 13D. Item 2 of the Schedule 13D is hereby amended by the addition of the following: According to a Schedule 13D (Amendment No. 11) filed by Fresenius SE on March 10, 2025, Fresenius SE is presently the beneficial owner of 83,780,382 shares of FME AG, constituting 28.6% of the outstanding shares of FME AG. On the date of this Schedule 13D (Amendment No. 4), FMCH is the beneficial owner of 18,312,735 shares of the Issuer's Common Stock, constituting approximately 11.8% of the Issuer's outstanding voting shares (calculated with reference to 155,118,816 shares outstanding as of May 5, 2025, as reported by the Issuer on the cover page of its quarterly report on Form 10-Q for the three months ended March 31, 2025). All such 18,312,735 Shares are issued and outstanding and owned directly by FMCH. Such 18,312,735 shares of Common Stock exclude any additional shares of Common Stock that may be issued pursuant to the terms of the Business Combination described in the Filing Persons' initial Schedule 13D, and the Filing Persons disclaim any present beneficial ownership of any such additional shares. FMCH possesses voting and dispositive power over the 18,312,735 shares of Common Stock reported in this Schedule 13D (Amendment No 4). FME AG is the indirect sole shareholder of FMCH may be deemed to be a beneficial owner of such shares. The decrease in the Filing Persons' percentage beneficial ownership from 14.2%, as reported in their Schedule 13D (Amendment No. 3) to 11.8%, as reported in this Schedule 13D (Amendment No. 4) results solely from an increase in the number of outstanding shares of the Issuer's Common Stock subsequent to the filing of Amendment No. 3 to this Schedule 13D. Neither of the Filing Persons has disposed of or acquired any shares of the Issuer's Common Stock subsequent to the filing of the initial Schedule 13D in September 2021. Fresenius Medical Care Holdings, Inc. /s/ Bryan Mello 05/22/2025 Fresenius Medical Care AG /s/ F. W. Maddux MD 05/22/2025 /s/ Christof Koester 05/22/2025